CL2012002404A1 - Compuestos derivados de urea, inhibidores de inmunoproteasomas; composición farmacéutica que comprende al compuesto; utiles en enfermedades inmunes, cancer, inflamacion, infecciones, enfermedad neurodegenerativa, entre otras. - Google Patents
Compuestos derivados de urea, inhibidores de inmunoproteasomas; composición farmacéutica que comprende al compuesto; utiles en enfermedades inmunes, cancer, inflamacion, infecciones, enfermedad neurodegenerativa, entre otras.Info
- Publication number
- CL2012002404A1 CL2012002404A1 CL2012002404A CL2012002404A CL2012002404A1 CL 2012002404 A1 CL2012002404 A1 CL 2012002404A1 CL 2012002404 A CL2012002404 A CL 2012002404A CL 2012002404 A CL2012002404 A CL 2012002404A CL 2012002404 A1 CL2012002404 A1 CL 2012002404A1
- Authority
- CL
- Chile
- Prior art keywords
- infections
- inflammation
- urea
- cancer
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000004202 carbamide Substances 0.000 title abstract 2
- 208000026278 immune system disease Diseases 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30936610P | 2010-03-01 | 2010-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012002404A1 true CL2012002404A1 (es) | 2012-12-21 |
Family
ID=43983939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012002404A CL2012002404A1 (es) | 2010-03-01 | 2012-08-31 | Compuestos derivados de urea, inhibidores de inmunoproteasomas; composición farmacéutica que comprende al compuesto; utiles en enfermedades inmunes, cancer, inflamacion, infecciones, enfermedad neurodegenerativa, entre otras. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9359398B2 (enExample) |
| EP (1) | EP2542238B1 (enExample) |
| JP (1) | JP6042724B2 (enExample) |
| KR (1) | KR20130075723A (enExample) |
| CN (1) | CN102892417A (enExample) |
| AU (1) | AU2011223795B2 (enExample) |
| BR (1) | BR112012022060A2 (enExample) |
| CA (1) | CA2791651C (enExample) |
| CL (1) | CL2012002404A1 (enExample) |
| CO (1) | CO6612265A2 (enExample) |
| CR (1) | CR20120451A (enExample) |
| CU (1) | CU20120125A7 (enExample) |
| DO (1) | DOP2012000238A (enExample) |
| EA (1) | EA201290844A1 (enExample) |
| EC (1) | ECSP12012140A (enExample) |
| MA (1) | MA34133B1 (enExample) |
| MX (1) | MX2012010017A (enExample) |
| PH (1) | PH12012501719A1 (enExample) |
| SG (1) | SG183843A1 (enExample) |
| WO (1) | WO2011109355A1 (enExample) |
| ZA (1) | ZA201206479B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006311584B2 (en) | 2005-11-09 | 2012-03-08 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| CN101506224B (zh) | 2006-06-19 | 2016-03-30 | 欧尼斯治疗公司 | 蛋白酶体抑制用的肽环氧酮 |
| PT2207791T (pt) | 2007-10-04 | 2016-07-12 | Onyx Therapeutics Inc | Inibidores da epoxi cetona protease de péptido cristalino e a síntese de ceto-epóxidos de aminoácidos |
| EP3090737A1 (en) | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| WO2011109355A1 (en) * | 2010-03-01 | 2011-09-09 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| JP2013525282A (ja) | 2010-04-07 | 2013-06-20 | オニキス セラピューティクス， インク． | 結晶質ペプチドエポキシケトンイムノプロテアソーム阻害剤 |
| TW201414751A (zh) | 2012-07-09 | 2014-04-16 | 歐尼克斯治療公司 | 肽環氧酮蛋白酶抑制劑之前驅藥物 |
| WO2014086664A1 (en) * | 2012-12-03 | 2014-06-12 | F. Hoffmann-La Roche Ag | Substituted triazole boronic acid compounds |
| CN105164117B (zh) * | 2013-03-14 | 2019-02-01 | 欧尼斯治疗公司 | 二肽和三肽环氧酮蛋白酶抑制剂 |
| CN105431447A (zh) * | 2013-03-15 | 2016-03-23 | 阿达拉塔合伙有限公司 | Pcsk9的小分子调节剂和其使用方法 |
| EP3092244B1 (en) | 2014-01-10 | 2019-08-14 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
| CN103804469B (zh) * | 2014-02-17 | 2016-04-06 | 苏州明锐医药科技有限公司 | 卡非佐米中间体的制备方法 |
| US11202817B2 (en) | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| CA2963198A1 (en) * | 2014-10-01 | 2016-04-07 | Merck Patent Gmbh | Boronic acid derivatives |
| CN106588965A (zh) * | 2015-10-15 | 2017-04-26 | 北京大学 | 脲拟肽硼酸化合物及其药物组合物、制备方法和用途 |
| US11066397B2 (en) | 2015-10-15 | 2021-07-20 | Cornell University | Proteasome inhibitors and uses thereof |
| EP3472151A4 (en) | 2016-06-21 | 2020-03-04 | Orion Ophthalmology LLC | CARBOCYCLIC PROLINAMIDE DERIVATIVES |
| FI3472149T3 (fi) | 2016-06-21 | 2023-11-09 | Orion Ophthalmology LLC | Heterosyklisiä prolinamidijohdannaisia |
| EP3694605A4 (en) | 2017-10-11 | 2021-10-27 | Cornell University | PEPTIDOMIMETIC INHIBITORS OF PROTEASOME |
| US11225493B2 (en) * | 2017-11-16 | 2022-01-18 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
| EP3710063A1 (en) * | 2017-11-16 | 2020-09-23 | Amgen Inc. | Stable compositions of pegylated carfilzomib compounds |
| LV15544A (lv) * | 2019-07-01 | 2021-01-20 | Latvijas Organiskās Sintēzes Institūts | Jauni borskābi saturoši peptidomimētiķi kā malārijas serīna proteāzes inhibitori |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| DE3827340A1 (de) * | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
| JPH0291023U (enExample) | 1989-01-05 | 1990-07-19 | ||
| US5441944A (en) | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
| US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
| US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JPH05506777A (ja) | 1990-03-05 | 1993-10-07 | セファロン、インコーポレーテッド | キモトリプシン様プロテアーゼ及びそれらの阻害剤 |
| US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| GB9300048D0 (en) | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
| TW380137B (en) | 1994-03-04 | 2000-01-21 | Merck & Co Inc | Process for making an epoxide |
| US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
| US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
| US6506876B1 (en) | 1994-10-11 | 2003-01-14 | G.D. Searle & Co. | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| DE19505263A1 (de) | 1995-02-16 | 1996-08-22 | Consortium Elektrochem Ind | Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| SI0932617T1 (en) | 1996-10-18 | 2002-06-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| DK0932617T3 (da) | 1996-10-18 | 2002-04-22 | Vertex Pharma | Inhibitorer af serinproteaser, især af hepatitis C-virus-NS3-protease |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| AU750207B2 (en) | 1997-06-13 | 2002-07-11 | Cydex Pharmaceuticals, Inc. | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
| US6133308A (en) | 1997-08-15 | 2000-10-17 | Millennium Pharmaceuticals, Inc. | Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
| US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| US6099851A (en) | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
| US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
| US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| CA2347275C (en) | 1998-10-20 | 2010-03-09 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
| US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
| US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| AU784304B2 (en) | 1999-10-20 | 2006-03-09 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| US20040106539A1 (en) | 2000-10-12 | 2004-06-03 | Ulrich Schubert | Agents for the treatment of viral infections |
| EP2251344B2 (en) | 2001-01-25 | 2024-04-24 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Formulation of boronic acid compounds |
| CA2447909C (en) | 2001-05-21 | 2011-04-05 | Alcon, Inc. | Use of proteasome inhibitors to treat dry eye disorders |
| WO2002096933A1 (en) * | 2001-05-30 | 2002-12-05 | Novartis Ag | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives |
| EP1463719A2 (en) | 2002-01-08 | 2004-10-06 | Eisai Co., Ltd | Eponemycin and epoxomicin analogs and uses thereof |
| US20040116329A1 (en) | 2002-01-29 | 2004-06-17 | Epstein Stephen E. | Inhibition of proteasomes to prevent restenosis |
| EP1496916A2 (en) | 2002-04-09 | 2005-01-19 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2003101481A1 (en) | 2002-06-03 | 2003-12-11 | Als Therapy Development Foundation | Treatment of neurodegenerative diseases using proteasome modulators |
| US20030224469A1 (en) | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
| WO2004010937A2 (en) | 2002-07-26 | 2004-02-05 | Advanced Research & Technology Institute At Indiana University | Method of treating cancer |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| SG175449A1 (en) | 2003-04-08 | 2011-11-28 | Novartis Ag | Organic compounds |
| ATE506456T1 (de) | 2003-06-10 | 2011-05-15 | David Gladstone Inst | Verfahren zur behandlung von lentivirusinfektionen |
| US7012063B2 (en) | 2003-06-13 | 2006-03-14 | Children's Medical Center Corporation | Reducing axon degeneration with proteasome inhibitors |
| AU2004312096A1 (en) | 2003-12-31 | 2005-07-21 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid |
| GB0400804D0 (en) | 2004-01-14 | 2004-02-18 | Innoscience Technology Bv | Pharmaceutical compositions |
| US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| JP5616569B2 (ja) | 2004-04-15 | 2014-10-29 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 酵素阻害のための化合物 |
| CN102875642A (zh) | 2004-05-10 | 2013-01-16 | 普罗特奥里克斯公司 | 用于酶抑制的化合物 |
| US20050256324A1 (en) | 2004-05-10 | 2005-11-17 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
| CA2584515A1 (en) | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Labeled compounds for proteasome inhibition |
| PL2260835T3 (pl) | 2004-12-07 | 2013-08-30 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
| US7468383B2 (en) * | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| WO2006099261A2 (en) * | 2005-03-11 | 2006-09-21 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
| US7998938B2 (en) | 2005-04-15 | 2011-08-16 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| AU2006311584B2 (en) | 2005-11-09 | 2012-03-08 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
| US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
| WO2007122686A1 (ja) | 2006-04-14 | 2007-11-01 | Eisai R & D Management Co., Ltd. | ベンズイミダゾール化合物 |
| DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
| CN101506224B (zh) | 2006-06-19 | 2016-03-30 | 欧尼斯治疗公司 | 蛋白酶体抑制用的肽环氧酮 |
| WO2008033807A2 (en) | 2006-09-13 | 2008-03-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic proteasome inhibitors for the treatment of cancer |
| AU2008209555A1 (en) | 2007-01-23 | 2008-07-31 | Gloucester Pharmaceuticals, Inc. | Combination therapy comprising romidepsin and I.A. bortezomib |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| EP2527347A1 (en) | 2007-08-06 | 2012-11-28 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| PT2207791T (pt) | 2007-10-04 | 2016-07-12 | Onyx Therapeutics Inc | Inibidores da epoxi cetona protease de péptido cristalino e a síntese de ceto-epóxidos de aminoácidos |
| EP2212334B1 (en) | 2007-10-16 | 2012-08-15 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| US7838673B2 (en) | 2007-10-16 | 2010-11-23 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
| WO2009067453A1 (en) | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinations of hdac inhibitors and proteasome inhibitors |
| SG194349A1 (en) | 2008-06-17 | 2013-11-29 | Millennium Pharm Inc | Boronate ester compounds and pharmaceutical compositions thereof |
| AR075090A1 (es) * | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| EP3090737A1 (en) | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| CN101928329B (zh) | 2009-06-19 | 2013-07-17 | 北京大学 | 三肽硼酸(酯)类化合物、其制备方法和应用 |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| WO2011109355A1 (en) * | 2010-03-01 | 2011-09-09 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| SG184222A1 (en) | 2010-03-31 | 2012-10-30 | Millennium Pharm Inc | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| JP2013525282A (ja) | 2010-04-07 | 2013-06-20 | オニキス セラピューティクス， インク． | 結晶質ペプチドエポキシケトンイムノプロテアソーム阻害剤 |
| FR2962092B1 (fr) * | 2010-06-30 | 2013-06-28 | Valeo Systemes Dessuyage | Adaptateur d'essuie-glace a contacts electriques |
-
2011
- 2011-03-01 WO PCT/US2011/026629 patent/WO2011109355A1/en not_active Ceased
- 2011-03-01 CA CA2791651A patent/CA2791651C/en active Active
- 2011-03-01 PH PH1/2012/501719A patent/PH12012501719A1/en unknown
- 2011-03-01 SG SG2012064531A patent/SG183843A1/en unknown
- 2011-03-01 EP EP11715320.5A patent/EP2542238B1/en active Active
- 2011-03-01 BR BR112012022060A patent/BR112012022060A2/pt not_active IP Right Cessation
- 2011-03-01 MX MX2012010017A patent/MX2012010017A/es active IP Right Grant
- 2011-03-01 US US13/580,112 patent/US9359398B2/en active Active
- 2011-03-01 EA EA201290844A patent/EA201290844A1/ru unknown
- 2011-03-01 CN CN201180022010XA patent/CN102892417A/zh active Pending
- 2011-03-01 JP JP2012556160A patent/JP6042724B2/ja active Active
- 2011-03-01 MA MA35248A patent/MA34133B1/fr unknown
- 2011-03-01 AU AU2011223795A patent/AU2011223795B2/en active Active
- 2011-03-01 KR KR1020127025901A patent/KR20130075723A/ko not_active Withdrawn
-
2012
- 2012-08-28 ZA ZA2012/06479A patent/ZA201206479B/en unknown
- 2012-08-29 DO DO2012000238A patent/DOP2012000238A/es unknown
- 2012-08-30 CU CU2012000125A patent/CU20120125A7/es unknown
- 2012-08-30 CR CR20120451A patent/CR20120451A/es unknown
- 2012-08-31 CL CL2012002404A patent/CL2012002404A1/es unknown
- 2012-09-04 EC ECSP12012140 patent/ECSP12012140A/es unknown
- 2012-09-28 CO CO12170402A patent/CO6612265A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CR20120451A (es) | 2012-10-16 |
| MA34133B1 (fr) | 2013-04-03 |
| CA2791651C (en) | 2019-08-20 |
| JP2013521295A (ja) | 2013-06-10 |
| CU20120125A7 (es) | 2012-11-15 |
| CO6612265A2 (es) | 2013-02-01 |
| CN102892417A (zh) | 2013-01-23 |
| US20130072422A1 (en) | 2013-03-21 |
| EA201290844A1 (ru) | 2013-03-29 |
| ZA201206479B (en) | 2015-08-26 |
| DOP2012000238A (es) | 2013-01-15 |
| ECSP12012140A (es) | 2012-10-30 |
| AU2011223795A1 (en) | 2012-09-20 |
| SG183843A1 (en) | 2012-10-30 |
| JP6042724B2 (ja) | 2016-12-14 |
| US9359398B2 (en) | 2016-06-07 |
| MX2012010017A (es) | 2012-10-01 |
| PH12012501719A1 (en) | 2012-11-12 |
| AU2011223795B2 (en) | 2015-11-05 |
| CA2791651A1 (en) | 2011-09-09 |
| BR112012022060A2 (pt) | 2018-05-08 |
| WO2011109355A1 (en) | 2011-09-09 |
| EP2542238A1 (en) | 2013-01-09 |
| KR20130075723A (ko) | 2013-07-05 |
| EP2542238B1 (en) | 2015-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012002404A1 (es) | Compuestos derivados de urea, inhibidores de inmunoproteasomas; composición farmacéutica que comprende al compuesto; utiles en enfermedades inmunes, cancer, inflamacion, infecciones, enfermedad neurodegenerativa, entre otras. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| MX370597B (es) | Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer. | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| MX391858B (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| SMT201600398B (it) | Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi | |
| BR112013020352A2 (pt) | composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CR20130550A (es) | Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| BR112015004547A2 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| CL2008003041A1 (es) | Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| MX367241B (es) | Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer. | |
| NZ626618A (en) | Hydroxamic acid derivatives and uses thereof | |
| ECSP12012348A (es) | Agentes inductores de apoptosis contra el cáncer y de enfermedades inmunes y autoinmunes | |
| BR112013031493A2 (pt) | composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto. | |
| CR20130081A (es) | Composición para el tratamiento de plantas y métodos para su uso |